Toll-like receptor 3 gene polymorphisms are not associated with the risk of hepatitis B and hepatitis C virus infection
Keyla Santos Guedes de Sá [1] , Orlando de Souza Pires-Neto [1] , Barbara Brasil Santana [1] , Samara Tatielle Monteiro Gomes [1] , Ednelza da Silva Graça Amoras [1] , Simone Regina da Silva Conde [2] , Sâmia Demachki [2] , Vânia Nakauth Azevedo [1] , Luiz Fernando Almeida Machado [1] , Rosimar Neris Martins-Feitosa [1] , Marluísa de Oliveira Guimarães Ishak [1] , Ricardo Ishak [1] and Antonio Carlos Rosário Vallinoto [1] [1]. Toll-like receptor 3 (TLR3) is a major intracellular receptor that recognizes viral double-stranded RNA (dsRNA) (1) and initiates infl ammatory responses against deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) viruses, such as hepatitis B virus (HBV) and hepatitis C virus (HCV). Therefore, TLR3 plays an important role in the immune response to infections caused by such viruses and might infl uence the chronicity of such viruses, eventually leading to liver cirrhosis and hepatocellular carcinoma ( 2) (3) (4) (5) . Furthermore, polymorphisms in the Toll-like receptor 3 gene have been associated with susceptibility to or the clinical progression of infection (6) (7) (8) (9) .
Single-nucleotide polymorphism (SNP) rs5743305 (-1077 T>A) is located in the promoter region of the TLR3 gene and might infl uence its transcription. SNP rs3775291 (1234 C>T) is a nonsynonymous mutation (Leu412Phe) located in the fourth exon and occurs very frequently in HCV carriers who require liver transplantation (6) . In addition, rs3775291 is a risk factor for chronic HBV infection (10) and has been associated with resistance to human immunodefi ciency virus (HIV) infection (11) (12) . Given these reports concerning the influence of the TLR3 gene on infections caused by HCV and HBV, the present study investigated the prevalence of TLR3 SNPs rs5743305 and rs3775291 in hepatitis patients who visited a northern Brazil hospital that is a regional reference for the treatment of hepatic diseases.
METHODS

Study population
In this study, samples were collected from 74 
RESULTS
The selected participants were consecutive patients, of both genders, with chronic HCV or HBV infection; their age ranged from 22 to 80 years. The control group consisted of 299 HCV-and HBVseronegative individuals of both genders and aged 19 to 68 years. All of the recruited individuals signed an informed consent form.
The inclusion criteria were as follows: individuals aged 18 years or older of either gender, hepatitis B surface antigen (HBsAg)-positive for more than six months, HCV RNApositive, and with or without a persistent elevated alanine aminotransferase (ALT) level. Individuals without a history of hepatobiliary disease or autoimmune hepatitis who did not meet the inclusion criteria, individuals co-infected with hepatitis D virus (HDV) and/or HIV, and patients who were previously or currently treated for HBV or HCV were excluded from the study.
This study was approved by the Research Ethics Committee of the Federal University of Para, protocol nº 684.432/2014, in accordance with resolution nº 466/2012 from the National Health Council, which addresses regulatory standards and guidelines for research involving humans.
Obtained samples and histopathological analysis
Blood samples were collected in vacuum tubes containing diaminoethanetetraacetic acid (EDTA) as an anticoagulant, and the plasma was separated by centrifugation and stored at -20°C until use. Biopsies were performed using a Tru-Cut needle and were guided by ultrasound. Each sample was divided into two parts. One part was subjected to histopathological examination after hematoxylin-eosin (HE), chromotrope aniline blue (CAB), Gomori's reticulin and Shikata's orcein staining in the Department of Anatomic Pathology at Federal University of Para (UFPA). The diagnosis followed the French classifi cation METAVIR (METAVIR Cooperative Study Group), which scores the activity of portal and periportal infl ammatory infi ltrates from 0 to 3 and any structural changes from 0 to 4. The remaining portion of each biopsy specimen was sent for genetic analysis at the Laboratory of Virology of the Institute of Biological Sciences/Federal University of Para (ICB/UFPA) and was stored at -70°C until the time of use.
Genetic analysis
Genomic DNA was extracted from total peripheral blood leukocytes following the protocol of a nucleic acid isolation kit (Gentra Systems, Inc., USA). The procedure included the following steps: cell lysis, protein precipitation, DNA precipitation, and DNA hydration. Data related to ALT, aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and prothrombin time (PT) quantifi cation were collected from the Virus Laboratory's database and the participants' clinical records.
The extracted DNA was subjected to real-time polimerase chain reaction (qPCR) using a Step One Plus Sequence Detector (Life Technologies, Foster City, CA, USA). For each assessed polymorphism, the assays included one pair of primers and one pair of probes VIC ® (VIC fl uorescent dye) and FAM 
Statistics
Genotype and allele frequencies were estimated by direct counting. Genotype frequencies and expected Hardy-Weinberg equilibrium were estimated with the chi-square test (χ 2 ) using the BioEstat 5.0 software (13) . A simple logistic regression analysis was performed to investigate the association of genetic models (i.e., codominant, dominant, recessive and overdominant) with the risk of HCV and HBV infection. The risk of disease progression was calculated as an odds ratio (OR) with a 95% confi dence interval (CI).
The allele, genotype and haplotype frequencies were compared between groups using the chi-square test (χ 2 ). To determine whether the variables AST, ALT, GGT and PT followed a normal distribution, D'Agostino's test was used, and the mean values of the laboratory markers were compared using analysis of variance (ANOVA). A p-value <0.05 was considered statistically signifi cant using the BioEstat 5.0 software (13) .
All studied groups were found to be in Hardy-Weinberg equilibrium, and no signifi cant differences in the allele, genotype and haplotype frequencies of the investigated polymorphisms were observed ( Table 1) . Nine haplotypes were observed in the patient and control groups, with haplotype TT/GA as the most frequent in the control and HCV-positive groups and haplotype TT/GG as the most frequent in the HBV-positive group ( Table 1) .
Comparisons of the polymorphisms, infl ammatory activity, degree of fi brosis and presence of cirrhosis in the chronically infected HCV and HBV patients ( Table 2 ) revealed no signifi cant associations. Additionally, none of the suggested genetic models (i.e., codominant, dominant, recessive or overdominant) was associated with the risk of infection with HBV and HCV ( Table 3) .
The mean values of ALT, AST, GGT and PT followed a normal distribution. The presence of allele A in genotypes TA/AA (rs5743305) was associated with higher AST (p<0.05) levels in HCV carriers compared to HBV-infected individuals (Figure 1) . The same results were found with respect to the GGT level in genotypes TT (rs5743305; p<0.05) and GG (rs3775291; p<0.05).
Alanine aminotransferase levels were higher (p<0.01) in HCV-infected subjects carrying the GG genotype (rs3775291) than in HBV-infected patients. However, GGT levels were higher in HCV patients than in HBV patients, independent of the polymorphism analyzed.
Finally, among the HCV-infected subjects, PT was higher in individuals exhibiting genotypes TA/AA (rs5743305; p<0.05) and GG (rs3775291; p<0.05) than in the HBV-infected group. The results of this study suggest that the investigated polymorphisms are not associated with susceptibility to HBV and HCV infection or with the infl ammatory activity, the degree of fi brosis or cirrhosis. Nevertheless, the results did suggest that polymorphisms might play a role in disease progression because genotypes TA/AA (rs5743305) and GG (rs3775291) appear to be associated with a greater degree of biliary and liver damage in HCV-infected individuals. These fi ndings are inconsistent with the results reported by Askar et al. (8) , who found no relationship between polymorphism rs5743305 and HCV chronicity.
TLR3 plays a signifi cant role in HCV and HBV infection because it is responsible for the production of interferon (IFN) and for the activation of interferon-stimulated genes (ISGs) and IFN regulatory factor 3 (IRF-3), which helps to maintains a low rate of viral replication (14) (15) (16) . Therefore, we suggest that the more severe liver damage that was observed in the HCV patients carrying genotypes TA/AA (rs5743305) and GG (rs3775291) occurs due to the increased production of proinfl ammatory cytokines, particularly TNF (tumor necrosis factors), IL-1 (interleukin 1), IL-6 and IFN-α, β and γ, by hepatic cells during liver injury; these cytokines are somehow related to the pathogenesis of the investigated viruses.
TLR3 activation effi ciently suppresses HBV replication through the stimulation of IFN-β in murine liver cells (17) . However, HBV polymerase inhibits IFN-β promoter region activity, thus blocking both IFN-β expression and TLR3-mediated antiviral activity (18) . In the case of HCV infection, an increase in HCV envelope protein E1E2 is associated with reduced TLR3 expression (16) . In addition, the reduced amounts of intracellular Toll-IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) that occur during HCV infection also impair TLR3 signaling (14) . Thus, we believe that the action of the polymorphisms investigated in this study is more relevant in HCV infection than in HBV infection, as HCV directly affects gene expression as an escape mechanism, which might be hindered by the location of polymorphism rs5743305 in the promoter region. As HBV reduces INF-β expression, the polymorphisms investigated in this study might lack this activity during infection.
Certain studies have demonstrated that allele A (rs3775291) reduces the ability of TLR3 to recognize double-stranded RNA, leading to decreased activation of nuclear factor kappalight-chain-enhancer of activated B cells (NF-kB) (19) (20) . Therefore, this allele might represent a protective factor against liver failure, as the infl ammatory response would not be exacerbated during the course of an HCV infection; in contrast, there is no relationship between this allele and HBV infection.
In chronic viral hepatitis, TLR3 expression is increased in intrahepatic biliary epithelial cells (21) and likely plays a role in the onset of biliary damage. Our results suggest that polymorphisms in the TLR3 gene (i.e., rs5743305 and rs3775291) might be associated with increased GGT levels in patients infected with HCV but not in patients infected with HBV.
The results of this study suggest that the infl uence of the investigated polymorphisms might be greater in HCV infection, contributing to increased liver damage in comparison to HBV infection. Finally, further studies with larger cohorts are needed to confi rm or refute the results and conclusions reported here. 
